Volume 121 Issue 8, 15 October 2019

Volume 121 Issue 8

Comment

  • Comment | | Open Access

    Anti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need for long-term treatment duration, using evidence from melanoma research, both published and in process.

    • Sarah Danson
    • , Jane Hook
    • , Helen Marshall
    • , Alexandra Smith
    • , Sue Bell
    • , Simon Rodwell
    •  & Pippa Corrie

Review Article

Article

Brief Communication

Correspondence